A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies

Chemotherapy Induced Anemia Clinical Trial

Official title:
A Randomized, Open-label, Active-controlled, Multicenter Phase 3 Study to Investigate the Efficacy and Safety of Roxadustat for Treatment of Anemia in Subjects Receiving Chemotherapy Treatment for Non-Myeloid Malignancies

Status Completed

Clinical Trial Summary

The main goal of this study is to evaluate the efficacy of roxadustat for treatment of anemia in participants with non-myeloid malignancies receiving multi-cycle treatments of myelosuppressive chemotherapy.

Clinical Trial Description

Participants who are eligible for participation will be randomized to roxadustat and SEPO® (recombinant human erythropoietin-α [rHuEPO-α]), and undergo a 12-week treatment period followed by a 4-week follow-up period. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05301517
Study type	Interventional
Source	FibroGen
Contact
Status	Completed
Phase	Phase 3
Start date	March 16, 2022
Completion date	April 21, 2023

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT00931606` - Study of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer (MK-7962-012)	Phase 2
Completed	`NCT00272662` - Study of Subcutaneously Administered Peginesatide in Anemic Cancer Patients Receiving Chemotherapy	Phase 2
Completed	`NCT00144495` - A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy	Phase 3
Not yet recruiting	`NCT06075030` - A Study of AND017 in Cancer Related Anemic Patients Receiving Chemotherapy	Phase 2
Completed	`NCT00144482` - A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy	Phase 3
Completed	`NCT04076943` - Evaluation of Efficacy and Safety of Roxadustat for the Treatment of Chemotherapy Induced Anemia	Phase 2